

**CURRICULUM VITAE  
SALLEY GIBNEY PELS, MD**

594 Eddy Street, MPS-122  
Tel 401-444-5171  
Fax 401-444-8845  
Email 1- [salley\\_pels@brown.edu](mailto:salley_pels@brown.edu)  
Email 2- [spels@lifespan.org](mailto:spels@lifespan.org)

EDUCATION

Undergraduate	Johns Hopkins University BA (Chemistry) 2000
Medical School	University of Vermont College of Medicine MD 2004

POSTGRADUATE TRAINING

Residency	Yale-New Haven Children's Hospital, Pediatrics, 2004-2007
Fellowship	Yale-New Haven Children's Hospital, Pediatric Hematology/Oncology, 2007-2010
Fellowship	Yale-New Haven Children's Hospital, Hemostasis Fellow, NHF-Baxter Clinical Fellowship Program, 2009-2011

POSTGRADUATE HONORS AND AWARDS

2010	Eberhard F. Mammen Young Investigator Award Winner 2009, Seminars in Thrombosis and Hemostasis
2009	ASH Travel Award, American Society of Hematology
2009	HTRS Young Investigators' Travel Award, Hemophilia and Thrombosis Research Society
2009- 2011	NHF-Baxter Clinical Fellow Award, National Hemophilia Foundation

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

2009	American Board of Pediatrics, Pediatrics
2010	Connecticut State Physician License #1.047779 (CSP.0047614)
2013	American Board of Pediatrics, Subspecialty Certification Pediatric Hematology Oncology

2019 Rhode Island State Medical License #16634  
2020 Massachusetts Emergency Temporary Medical License ETL #406  
(effective 3/30/2020- present)

#### ACADEMIC APPOINTMENTS

2010- 13 Instructor, Section of Hematology Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT  
2013- 2019 Assistant Professor, Section of Hematology Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT  
2019- present Associate Professor, Division of Hematology Oncology, Department of Pediatrics, Brown University, Warren Alpert School of Medicine, Providence, RI

#### HOSPITAL APPOINTMENTS

2012- 18 Associate Medical Director, Yale Hemophilia Center, Section of Hematology Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT  
2018- 2019 Co-Medical Director, Yale Hemophilia Center, Section of Hematology Oncology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT  
2019- present Director, Rhode Island Hemostasis and Thrombosis Center, Hasbro Children's Hospital/ Rhode Island Hospital, Providence, RI

#### HOSPITAL COMMITTEES

2010-2019 Member, Blood Transfusion and Tissue Banking Committee, Yale-New Haven Hospital  
2012-2016 Member, Blood Stream Infection (BSI) Committee, Yale-New Haven Children's Hospital  
2018-2019 Member, Children's Hospital CVC-VTE Steering Committee, Yale-New Haven Children's Hospital  
2018- 2019 Subject Matter Expert, Northeast Purchasing Coalition and Yale-New Haven Hospital Systems, Pharmacy Services  
2019- present Member, Pediatric Zero Harm CLABSI/VTE Team, Hasbro Children's Hospital/Rhode Island Hospital  
2019- present Member, Pediatric Trauma VTE Working Group, Hasbro Children's Hospital/Rhode Island Hospital  
2019- present Member, 340B Steering Committee, Rhode Island Hospital

#### UNIVERSITY COMMITTEES

2007- 2009 Fellow Representative, Graduate Medical Education Committee, Yale-New Haven Medical Center  
2013- 2019 Faculty Member, Clinical Competency Committee, Pediatric Hematology Oncology Fellowship Program, Department of Pediatrics, Yale University School of Medicine

- 2014-2017 Faculty Member, Mentor, Yale Pediatric Residency Mentoring Program, Yale University School of Medicine
- 2014- 2019 Faculty Member, Reviewer, Yale Pediatrics Research Forum, Yale University School of Medicine

#### MEMBERSHIP IN SOCIETIES

- 2007- present Associate Member, American Society of Hematology (ASH)
- 2007- present Associate Member, Children’s Oncology Group (COG)
- 2007- 2012 Associate Member, American Society of Pediatric Hematology Oncology (ASPHO)
- 2008- present Member, Hemostasis Thrombosis Research Society (HTRS)
- 2012- 2014 Member, American Society of Pediatric Hematology Oncology (ASPHO)
- 2013- present Member, Quality Improvement Subcommittee Member (2014-2019), American Thrombosis Hemostasis Network (ATHN)
- 2013- 2019 Board of Directors, Nominations Subcommittee (2014-2019), Hemophilia Alliance
- 2018-2019 Member, Board of Directors, Thrombosis Hemostasis Society of North America (THSNA)
- 2019- present Member, Steering Committee, North American Pediatric Aplastic Anemia Consortium (NAPAAC)
- 2019- presents Member, American Academy of Pediatrics (AAP), Section on Hematology Oncology (SOHO)
- 2019- present Member, American Society of Pediatric Hematology/Oncology (ASPHO)
- 2020- present Member, Joint ASPHO/AAP SOHO Transfusion Medicine Work Group (term 1/2020-1/2023)
- 2019- present Member, Foundation for Women and Girls with Blood Disorders (FWGBD), Learning Action Network (LAN) member

#### PUBLICATIONS LIST

##### ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. Romanowski MJ, **Gibney (Pels) SA**, Burley SK; Crystal structure of the Escherichia coli SbmC protein that protects cells from the DNA replication inhibitor microcin B17. *Proteins*. 2002 May 15;47(3):403-7.

##### BOOKS AND BOOK CHAPTERS

2. **Pels SG**, Paidas MJ. Microangiopathic disorders in pregnancy. *Hematol Oncol Clin North Am*. 2011 Apr;25(2):311-22.
3. **Pels SG**. Current therapies in primary immune thrombocytopenia; *Semin Thromb Hemost*. 2011 Sep;37(6):621-30. Epub 2011 Nov 18.

##### CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

4. Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S; PRESERVE-1 Study Group. Exploring the role of antithrombin replacement for the treatment of preeclampsia: a prospective randomized evaluation of the safety and efficacy of recombinant antithrombin in very preterm preeclampsia (PRESERVE-1). *Am J Reprod Immunol.* 2013 Jun;69(6):539-44. (*Local Co-PI- PRESERVE-1 Trial, 2013-2017*)
5. Konkle BA, Johnsen JM, Wheeler M, Watson C, Skinner M, Pierce GF; My Life Our Future programme. Genotypes, phenotypes and whole genome sequence: Approaches from the My Life Our Future haemophilia project. *Haemophilia.* 2018 May;24 Suppl 6:87-94. (*Local PI- My Life Our Future: Genotyping for Progress in Hemophilia, 2014-2017*)
6. Johnsen JM, Fletcher SN, Huston H, Roberge S, Martin BK, Kircher M, Josephson NC, Shendure J, Ruuska S, Koerper MA, Morales J, Pierce GF, Aschman DJ, Konkle BA. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. *Blood Adv.* 2017 May 18;1(13):824-834. (*Local PI- My Life Our Future: Genotyping for Progress in Hemophilia, 2014-2017*)
7. Action Guide for Improving Care for People with Bleeding Disorders, Adapted by the American Thrombosis and Hemostasis Network (ATHN) and Dartmouth Institute Microsystem Academy, June 2016 (*Physician member, Quality Improvement Working group member, Editor*)
8. Hemophilia Alliance Bleeding Disorders Product Guide, 1<sup>st</sup> Edition, 2017 (*Board member, Content Expert, Editor*)

#### ABSTRACTS

9. Reeves, R.H., Wiltshire, T., Pletcher, M., Lund, J., Cole, S., Cabin, D., Villanueva, M., **Gibney (Pels), S.**, Aquino, V. *Sequence ready template maps for mouse regions of conserved synteny with human chromosome 21.* 1999 Eighth International Meeting on Chromosome 21 and Down Syndrome, Rehovet, Israel.
10. Pletcher, M.T., **Gibney (Pels), S.**, Chen, F., Do, T., Do, A., Malaj, E., Roe, B.A., Reeves, R.H. *Analysis of chromosome evolution by comparative sequence analysis.* 2000 Genetics 2000, Visions of the Future, Vancouver, B.C.
11. **Pels, S.G., Tang, C., Ertem, M., Beardsley, D.S.** *IVIg Alters Fc $\gamma$ RII Balance on Human Macrophages: A Mechanism for its Therapeutic Effect in Immune Thrombocytopenia. Oral Presentation and Poster Session, Hemophilia Thrombosis Research Society Annual Scientific Symposium, Chicago, IL, April 2009.*
12. **Pels, S.G., Tang, C., Ertem, M., Beardsley, D.S.** *High-Dose IgG Alters the Relative Expression of Fc $\gamma$ RIIA and Fc $\gamma$ RIIB On Human Macrophages: A Mechanism for IVIg Therapy in Human Immune Thrombocytopenia, Oral Presentation, 51<sup>st</sup> Annual ASH Meeting, New Orleans, LA, December 2009.*

13. Martin JR, **Pels SG**, Paidas M, Seli E. Assisted reproduction in a patient with Klippel Trenaunay syndrome: management of thrombophilia and consumptive coagulopathy. *J Assist Reprod Genet.* 2010 Dec 29.
14. Min Li, Chang-Ching Yeh, Takugo Cho, **Salley Pels**, S. Joseph Huang. *The Immune Balance of Tumor Necrosis Factor Superfamily at Fetal-Maternal Interface in Response to Pro-inflammatory Stimuli.* Poster, 59<sup>th</sup> Annual SGI Meeting, San Diego, CA, March 2012.
15. Katelyn E Gagne, Roxanne Ghazvinian, Daniel Yuan, Rebecca L. Zon, Kelsie Storm, MD, Magdalena Mazur-Popinska, MD, Laura Andolina, MS, Halina Bubala, MD, PHD, Sydonia Golebiowska, MD, Meghan A. Higman, MD, PHD, Krzysztof Kalwak, MD, PHD, Peter Kurre, MD, Michal Matysiak, MD, PHD, Edyta Niewiadomska, MD, PHD, **Salley Pels, MD**, Mary Jane Petruzzi, MD, Aneta Pobudejska-Pieniazek, MD, Tomasz Szczepanski, MD, PHD, Mark D Fleming, D.Phil., M.D., Hanna T. Gazda, MD, PHD and Suneet Agarwal, MD, PHD. *Pearson Marrow Pancreas Syndrome In a Cohort Of Diamond Blackfan Anemia Patients.* Poster, 55<sup>th</sup> Annual ASH Meeting, New Orleans, LA, December 2013.
16. Gagne KE, Ghazvinian R, Yuan D, Zon RL, Storm K, Mazur-Popinska M, Andolina L, Bubala H, Golebiowska S, Higman MA, Kalwak K, Kurre P, Matysiak M, Niewiadomska E, **Pels S**, Petruzzi MJ, Pobudejska-Pieniazek A, Szczepanski T, Fleming MD, Gazda HT, Agarwal S. Pearson marrow pancreas syndrome in patients suspected to have Diamond Blackfan anemia. *Blood.* 2014 Apr 15.
17. Madrid DJ, Gargiulo J., Marino S., Bisson E., Selander K., Zarnetske T., Carbonella J., Bernier P., Kupfer, G, **Pels S.**; *Adolescent Transition Quality Improvement Collaborative: The Yale HTC Experience*; Oral Presentation and Poster Session; American Thrombosis Hemostasis Network Data Summit, Chicago, IL, September, 2016.
18. Ghoshal S, Bronen RA, McCarthy PL, **Pels SG**, Beslow LA. Acute Stroke in a Girl With an Absent Radial Pulse. *Pediatr Neurol.* 2016 Sep;62:77-8.
19. Maracaja D, Puthenpura V, **Pels S**, O'Malley D, Sklar J, Finberg K, Xu M. EBV-positive primary large B-cell lymphoma: highlighting the role of XPO1 mutation in the diagnosis of mediastinal lymphomas. Accepted Poster presentation at American Society of Clinical Pathology (ASCP) Annual Meeting, September 2019; Phoenix, AZ.

#### SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

20. **Salley Pels, MD** and Jim Munn, RN; “Strategies for Improving Hemophilia Patients’ Quality of Life and Patient-Reported Outcomes.” The Blood CME Center, August 15, 2014.
21. Beslow, L., **Pels, S.**, Seashore, M., Ment, L.; Pediatric Stroke Card for Yale Pediatric and Neurology Residents, August, 2010, with updates 2012,2013,2014, and 2015.
22. **Pels, S.**, Rabin, D., Lee, A., Tormey, C., Hendrickson, J., Cromwell, C., Gallagher, P., Kupfer, G, Paidas, M.; Personalizing the Management of Hemophilia; *Yale CME and France Foundation*, November 2015.

#### INVITED PRESENTATIONS

#### PEER-REVIEWED

### **International/National**

1. Hemophilia Thrombosis Research Society Annual Scientific Symposium, Chicago, IL: “IVIG Alters FcγRII Balance on Human Macrophages: A Mechanism for its Therapeutic Effect in Immune Thrombocytopenia”, April 2009
2. 51<sup>st</sup> Annual ASH Meeting, New Orleans, LA: “High-Dose IgG Alters the Relative Expression of Fcγ RIIA and Fcγ RII B On Human Macrophages: A Mechanism for IVIG Therapy in Human Immune Thrombocytopenia”, December 2009

### NON-PEER-REVIEWED

#### **International/National**

1. Salley Pels, MD and Jim Munn, RN; “Strategies for Improving Hemophilia Patients’ Quality of Life and Patient-Reported Outcomes.” The Blood CME Center, Online-Webinar, August 15, 2014
2. Hemophilia Alliance Member Meeting, Phoenix, AZ: “Hemophilia Factor Products: Review of current therapies and What’s new in 2014” January 2014.
3. Salley Pels, MD, Michael Paidas, MD, Peter Kouides, Barbara Konkle, Scott Kaatz, Richard Marlar; “Difficult Cases Expert Panel”; Plenary Session, Thrombosis Hemostasis Societies of North America, San Diego, CA, March 2018.

#### **Regional**

4. Salley Pels, MD and Kate Quint, LCSW; “Adolescent Transition Quality Improvement Collaborative: Pilot Site and Coaching Perspectives.” HHS Region 1 New England Hemophilia Treatment Centers Annual Meeting, Hartford CT, May 2016.
5. Salley Pels, MD; Keynote Speaker “von Willebrand Disease: The most common bleeding disorder your friends have never heard of!” New England Hemophilia Association, Inaugural von Willebrand Disease Retreat, Farmington CT, July 28, 2018.
6. Salley Pels, MD; “von Willebrand Disease” New England Hemophilia Association, Webinar, September 2018.
7. Salley Pels, MD; “Adolescent Transition Quality Improvement Collaborative: The Yale HTC Experience”, Hasbro Children’s Hospital, Providence RI, December 2018.
8. Salley Pels, MD; “Difficult Cases in Hemostasis” HHS Region 1/2 New England Hemophilia Treatment Centers Annual Meeting, New York City, NY May 2019.
9. Salley Pels, MD, Emily Bisson, APRN, Yvonne Tousignant, RN, Virginia Cerby, LCSW, Kristin Mooney, LCSW, “Medical Panel Discussion: Emerging Therapies” New England Hemophilia Association Fallfest, Warwick RI, October 2019
10. Salley Pels, MD; Hemophilia: From Ancient History to *Ancient History*. Rhode Island Hospital, Hasbro Children’s Hospital, Pediatric Grand Rounds, February 2020.

### GRANTS

### **Fellowship Training Awards**

1. Hematology Training Grant, T32, National Institutes of Health (NIH)  
PI: Bernard Forget; Role: Trainee; Project period: 7/2008 – 6/2009
2. NHF-Baxter Clinical Fellowship Award, National Hemophilia Foundation (NHF);  
PI: Salley Pels, MD; Project period: 7/2009 – 6/2011
3. Child Health Research Center Award, CHRC, National Institutes of Health (NIH);  
PI: Clifford Bogue, MD; Role: Instructor; Project period: 1/2011-12/2012

### **Government Sponsored Clinical Trial Research**

4. Centers for Disease Control (CDC) American Thrombosis Hemostasis Network (ATHN) Registry for Bleeding Disorders Surveillance; Local PI: Salley Pels, MD (\$3500); Project period: 3/1/2014- 5/30/2019
5. ATHN, NHF (National Hemophilia Foundation), Puget Sound Blood Center and Biogen Idec Hemophilia; My Life Our Future: Genotyping for Progress in Hemophilia; Local PI: Salley Pels, MD (\$3500); Project period: 4/1/2014- 12/15/2017
6. National Heart, Lung and Blood Institute (NHLBI) and Johns Hopkins All Children's Hospital; Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT); Local PI: Salley Pels, MD; Project period: 9/1/2014- 11/17/17
7. Maternal Child Health Bureau- Health Resources and Services Administration Regional Hemophilia Network (340B Hemophilia Factor Program); MCHB-HRSA (with 340B factor program)); Local PI: Gary Kupfer, MD; Role: Co-PI; (\$18,826); Project period: 6/1/2018- 5/30/2019
8. Maternal Child Health Bureau- Health Resources and Services Administration Regional Hemophilia Network (340B Hemophilia Factor Program); MCHB-HRSA (with 340B factor program)); Local PI (as of 7/2019): Salley Pels, MD; Project period: 6/1/2019- present
9. Centers for Disease Control (CDC) American Thrombosis Hemostasis Network (ATHN) Registry for Bleeding Disorders Surveillance; Local PI (as of 7/2019): Salley Pels, MD; Project period: 6/18/2014- present

### **Other Sponsored Clinical Trial Research**

10. McMaster University; WAPPS-HEMO: Web-based Application for the Population Pharmacokinetic Service-Hemophilia; Local PI: Salley Pels, MD; Project Period: 6/5/2006- 3/25/2020
11. American Thrombosis and Hemostasis Network (ATHN ); ATHN DataSet; Local PI: Salley Pels, MD; Project Period: 6/7/2012- present

12. American Thrombosis and Hemostasis Network (ATHN); ATHN Data Quality Counts, PI: Salley Pels, MD; Project Period: 9/1/19-8/31/20

13. ATHN in collaboration with Takeda; ATHN9: Severe vWD Natural History Study; Local PI: Salley Pels, MD; 11/27/2019- present

**Industry Sponsored Clinical Trial Research**

14. ATHN in collaborataion with Shire, CSL Behring, Bioverativ Therapeutics Inc., Bayer; ATHN2, Factor Switching Study; Local PI: Salley Pels, MD; Project period: 2017- 2019 (ongoing at Yale)

**Forthcoming Studies**

15. Octapharma; Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP); Local PI: Salley Pels, MD; estimated to start 2020

UNIVERSITY TEACHING, ADVISING and MENTORING ROLES

TEACHING:

**Yale University School of Medicine**

Name of Series	Frequency of Presentation	Subject of Presentation
Pediatric Hematology-Oncology Fellow’s Conference	3-4 times yearly	Topics in hemostasis and thrombosis (eg. DVT, anticoagulation, bleeding disorders, platelet disorders, emergency care of hemophilia & von Willebrand disease)
Medical Student, Pediatric Rotation Lecture Series	1-3 times yearly	Topics in hemostasis and thrombosis
Benign Hematology Conference Adult and Pediatric Fellows	5-6 times yearly	Topics in hemostasis and thrombosis
Pediatric Hematology Oncology Tumor Board	1-3 times yearly	Topics in pediatric oncology
Pediatric Hematology Oncology Leukemia/Lymphoma Board	4-5 times yearly	Topics in leukemia and lymphoma

**The Warren Alpert Medical School of Brown University**

Name of Series	Frequency of Presentation	Subject of Presentation
Pediatric Hematology-Oncology Fellow’s Conference	3-4 times yearly	Topics in hemostasis and thrombosis (eg. DVT, anticoagulation, bleeding

		disorders, platelet disorders, emergency care of hemophilia & von Willebrand disease)
Benign Hematology Conference Adult and Pediatric Fellows	5-6 times yearly	Topics in hemostasis and thrombosis
MS-2 Hematology Course, Small Group Faculty	3-6 times yearly	Topics in hematology

#### ADVISING AND MENTORING:

1. Faculty Mentor, Pediatric Hematology Oncology Fellowship Program, Yale University  
Mentee: David (Jeremy) Madrid, DO (2015-2018)  
Clinical mentor and advisor throughout his fellowship, he attended my weekly clinics and weekly meetings of the Yale Hemophilia Treatment Center, including participating in QI work of the center. He successfully completed fellowship and had several publications from his laboratory research during this time. He is now an attending physician at Dartmouth-Hitchcock Medical Center specializing in Pediatric Hematology and Hemophilia care.
2. Faculty Mentor/Clinical Coach, Yale Interprofessional Longitudinal Clinical Experience, Yale University (2017-2019)  
Clinical skills teaching and mentorship of a group of multidisciplinary students in MD, APRN, PA programs at Yale for two groups of 4 students, years 2017-18 and 2018-19.
3. Pediatrics Clerkship Preceptor, Yale University School of Medicine (2010-2019)  
Clinical skills and rounding, small group discussions and periodic formal lectures to medical students pertaining to Pediatric Hematology Oncology patient population both on inpatient unit and outpatient setting.
4. Faculty Small Group Leader, MS-2 Hematology Course (Jan 2020)  
Facilitated small group of 10 medical students during their Hematology core course. Lead discussions, reviewed basic pathophysiological content and translation to clinical care.

#### HOSPITAL TEACHING, ADVISING and MENTORING ROLES

##### TEACHING:

##### **Yale-New Haven Hospital System**

Name of Series	Frequency of Presentation	Subject of Presentation
Pediatric Resident Conference	1-2 times yearly	Topics in hematology (eg. Blood products, Evaluation of Bleeding, Thrombosis and Thrombophilia)

Yale Trauma Conference	Once, 6/2015	Title: "Approach to the Pediatric Trauma Patient with a Bleeding Disorder"
PICU Fellows Conference	Periodically, last 9/2016	Title: "Coagulopathy in the Pediatric ICU"
Bridgeport Pediatric Grand Rounds	Once, 1/2017	Title: "Thrombotic Disorders: A Primer for the General Pediatrician"
NICU Fellows Conference	Periodically, 3/2019	Title: "Coagulopathy in the Neonatal ICU"
Cardiology Fellows Conference	Periodically, 5/2019	Title: "Coagulopathy in the Pediatric Cardiology Patient"

**Hasbro Children's Hospital/Rhode Island Hospital**

Name of Series	Frequency of Presentation	Subject of Presentation
Pediatric Resident Wards Teaching	Monthly	Topics in hematology (eg. Blood products, Evaluation of Bleeding, Thrombosis and Thrombophilia)

**ADVISING AND MENTORING:**

1. Matthew Merguerian, MD PhD  
 Pediatric Resident, Yale-New Haven Children's Hospital (2014-2017)  
 Mentorship and advising through the Yale Pediatric Resident mentorship program. Matthew successfully completed his residency and is now in his third year of Pediatric Hematology Oncology Fellowship at Johns Hopkins University